The ethical conundrum: Conflicting advocacy positions in advanced heart failure therapy.
Adult
Cardiotonic Agents
/ therapeutic use
Female
Heart Failure
/ therapy
Heart Transplantation
/ ethics
Heart-Assist Devices
/ ethics
Hospitalization
/ statistics & numerical data
Humans
Male
Palliative Care
Patient Advocacy
/ standards
Patient Selection
Practice Guidelines as Topic
/ standards
Prognosis
Young Adult
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
02
12
2018
accepted:
20
01
2019
pubmed:
29
1
2019
medline:
2
5
2020
entrez:
29
1
2019
Statut:
ppublish
Résumé
It is estimated that nearly 6.5 million Americans over the age of 20 suffer from heart failure. Heart failure is the leading cause of hospitalization in patients over 65 years of age, and carries with it a 5-year mortality of nearly 50%. Despite advances in medical therapy, treatment for medically refractory end-stage, advanced heart failure is limited to heart transplant, mechanical circulatory support (MCS), or palliative care only. Patient selection in advanced heart failure (AHF) therapy is complex. Not only are the patients medically complicated, but providers are biased by their individual and collective experience with similar and dissimilar patients. Clinicians caring for AHF patients balance competing clinical and ethical demands, which appropriately leads to professional debate and disagreement. These debates are constructive because they clarify ethical and professional commitments and help to ensure fair and equitable treatment of AHF patients.
Substances chimiques
Cardiotonic Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13489Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.